Association of Race/Ethnicity With Overall Survival Among Patients With Colorectal Liver Metastasis

Background/Aim. Liver resection is the treatment of choice for solitary colorectal liver metastases in suitable candidates. Recently, radiofrequency ablation (RFA) has become a very popular procedure in the treatment of liver metastases. The aim of this study was to compare outcomes in patients with solitary colorectal liver metastasis who had been subjected to resection or ablation. Methods. In this retrospective study we analyzed and compared patients with solitary colorectal liver metastases treated by resection or ablation in the University Hospital Centre ?Dr Dragisa Misovic? in Belgrade from January 2002 until December 2009. Results. In this study 94 (67.1%) patients underwent resection whereas 46 (32.9%) patients underwent RFA. Most of the resected patients (59.6%) required major hepatectomy. The median follow-up time was 28.4 months. Tumor ablation was a significant predictor of the overall survival (p = 0.002; OR 3.75; 95% CI 1.696-8.284). Our study demonstrated longer disease free-survival in the group of resected patients compared to the RFA group (37.6 vs 22.3 months, p = 0.073). The median overall survival was 56.3 months for patients who underwent resection vs 25.1 months for those in the RFA group (p = 0.005). Conclusion. This study shows that the patients with solitary hepatic colorectal cancer metastases should be considered for hepatic resection whenever it is feasible, because this procedure provides superior long-term survival as compared to radiofrequency ablation.

Download Full-text

365. A neutrophil to lymphocyte ratio of 2 prior to liver resection predicts disease-free and overall survival in patients with colorectal liver metastasis

European Journal of Surgical Oncology ◽

10.1016/j.ejso.2014.08.355 ◽

2014 ◽

Vol 40 (11) ◽

pp. S141

Author(s):

A. Giakoustidis ◽

K. Neofytou ◽

A. Khan ◽

S. Mudan

Keyword(s):

Overall Survival ◽

Liver Resection ◽

Liver Metastasis ◽

Colorectal Liver Metastasis ◽

Neutrophil To Lymphocyte Ratio ◽

Lymphocyte Ratio ◽

Disease Free

Download Full-text

Perioperative chemotherapy with or without cetuximab in patients (pts) with resectable colorectal liver metastasis (CRLM): Mature analysis of overall survival (OS) in the New EPOC randomised controlled trial

Annals of Oncology ◽

10.1093/annonc/mdx393.010 ◽

2017 ◽

Vol 28 ◽

pp. v162 ◽

Cited By ~ 2

Author(s):

J. Bridgewater ◽

S. Pugh ◽

A. Whitehead ◽

L. Stanton ◽

Z. Eminton ◽

...

Keyword(s):

Overall Survival ◽

Liver Metastasis ◽

Randomised Controlled Trial ◽

Colorectal Liver Metastasis ◽

Controlled Trial ◽

Perioperative Chemotherapy ◽

Randomised Controlled ◽

Mature Analysis

Download Full-text

Successful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis

10.31234/osf.io/83zs2 ◽

2020 ◽

Author(s):

Lungwani Muungo

Keyword(s):

Liver Metastasis ◽

Colorectal Liver Metastasis ◽

Surgical Intervention ◽

Liver Volume ◽

Sigmoid Colon Cancer ◽

Remnant Liver ◽

Future Remnant Liver ◽

The Right ◽

Synchronous Colorectal Liver Metastasis ◽

Right Hepatic Vein

A 72-year-old woman with a sigmoid colon cancer anda synchronous colorectal liver metastasis (CRLM), whichinvolved the right hepatic vein (RHV) and the inferiorvena cava (IVC), was referred to our hospital. Themetastatic lesion was diagnosed as initially unresectablebecause of its invasion into the confluence of theRHV and IVC. After she had undergone laparoscopicsigmoidectomy for the original tumor, she consequentlyhad 3 courses of modified 5-fluorouracil, leucovorin,and oxaliplatin (mFOLFOX6) plus cetuximab. Computedtomography revealed a partial response, and theconfluence of the RHV and IVC got free from cancerinvasion. After 3 additional courses of mFOLFOX6 pluscetuximab, preoperative percutaneous transhepaticportal vein embolization (PTPE) was performed tosecure the future remnant liver volume. Finally, a righthemihepatectomy was performed. The postoperativecourse was uneventful. The patient was dischargedfrom the hospital on postoperative day 13. She hadneither local recurrence nor distant metastasis 18 moafter the last surgical intervention. This multidisciplinarystrategy, consisting of conversion chemotherapy usingFOLFOX plus cetuximab and PTPE, could contributein facilitating curative hepatic resection for initiallyunresectable CRLM.Key words: Initially unresectable; Colorectal liver metastasis;Conversion chemotherapy; Cetuximab; Percutaneoustranshepatic portal vein embolization

Download Full-text

Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients

Hepatology International ◽

10.1007/s12072-021-10151-4 ◽

2021 ◽

Author(s):

Maaike Biewenga ◽

Monique K. van der Kooij ◽

Michel W. J. M. Wouters ◽

Maureen J. B. Aarts ◽

Franchette W. P. J. van den Berkmortel ◽

...

Keyword(s):

Overall Survival ◽

Liver Metastasis ◽

Combination Therapy ◽

Real World ◽

Cytotoxic T Lymphocyte ◽

Checkpoint Inhibitor ◽

Checkpoint Inhibitors ◽

Progression Free Survival ◽

Negative Effect ◽

Melanoma Patients

Abstract Background Checkpoint inhibitor-induced hepatitis is an immune-related adverse event of programmed cell death protein 1 (PD-1) inhibition, cytotoxic T-lymphocyte associated 4 (CTLA-4) inhibition or the combination of both. Aim of this study was to assess whether checkpoint inhibitor-induced hepatitis is related to liver metastasis and outcome in a real-world nationwide cohort. Methods Data from the prospective nationwide Dutch Melanoma Treatment Registry (DMTR) was used to analyze incidence, risk factors of checkpoint inhibitor-induced grade 3–4 hepatitis and outcome. Results 2561 advanced cutaneous melanoma patients received 3111 treatments with checkpoint inhibitors between May 2012 and January 2019. Severe hepatitis occurred in 30/1620 (1.8%) patients treated with PD-1 inhibitors, in 29/1105 (2.6%) patients treated with ipilimumab and in 80/386 (20.7%) patients treated with combination therapy. Patients with hepatitis had a similar prevalence of liver metastasis compared to patients without hepatitis (32% vs. 27%; p = 0.58 for PD-1 inhibitors; 42% vs. 29%; p = 0.16 for ipilimumab; 38% vs. 43%; p = 0.50 for combination therapy). There was no difference in median progression free and overall survival between patients with and without hepatitis (6.0 months vs. 5.4 months progression-free survival; p = 0.61; 17.0 vs. 16.2 months overall survival; p = 0.44). Conclusion Incidence of hepatitis in a real-world cohort is 1.8% for PD-1 inhibitor, 2.6% for ipilimumab and 20.7% for combination therapy. Checkpoint inhibitor-induced hepatitis had no relation with liver metastasis and had no negative effect on the outcome.

Download Full-text